title: The TNF-family cytokine TL1A inhibits proliferation of human activated B cells.
abstract: Death receptor (DR3) 3 is a member of the TNFR superfamily. Its ligand is TNF-like ligand 1A (TL1A), a member of the TNF superfamily. TL1A/DR3 interactions have been reported to modulate the functions of T cells, NK, and NKT cells and play a crucial role in driving inflammatory processes in several T-cell-dependent autoimmune diseases. However, TL1A expression and effects on B cells remain largely unknown. In this study, we described for the first time that B cells from human blood express significant amounts of DR3 in response to B cell receptor polyclonal stimulation. The relevance of these results has been confirmed by immunofluorescence analysis in tonsil and spleen tissue specimens, which showed the in situ expression of DR3 in antigen-stimulated B cells in vivo. Remarkably, we demonstrated that TL1A reduces B-cell proliferation induced by anti-IgM-antibodies and IL-2 but did not affect B-cell survival, suggesting that TL1A inhibits the signal(s) important for B-cell proliferation. These results revealed a novel function of TL1A in modulating B-cell proliferation in vitro and suggest that TL1A may contribute to homeostasis of effector B-cell functions in immune response and host defense, thus supporting the role of the TL1A/DR3 functional axis in modulating the adaptive immune response.
authors.affiliation: Department of Medicine, Section of Hematology, University of Verona, Verona, Italy.
authors.forename: Chiara
authors.initials: C
authors.lastname: Cavallini
authors.forename: Ornella
authors.initials: O
authors.lastname: Lovato
authors.forename: Anna
authors.initials: A
authors.lastname: Bertolaso
authors.forename: Luciano
authors.initials: L
authors.lastname: Pacelli
authors.forename: Elisa
authors.initials: E
authors.lastname: Zoratti
authors.forename: Elisabetta
authors.initials: E
authors.lastname: Zanolin
authors.forename: Mauro
authors.initials: M
authors.lastname: Krampera
authors.forename: Alberto
authors.initials: A
authors.lastname: Zamò
authors.forename: Cristina
authors.initials: C
authors.lastname: Tecchio
authors.forename: Marco A
authors.initials: MA
authors.lastname: Cassatella
authors.forename: Giovanni
authors.initials: G
authors.lastname: Pizzolo
authors.forename: Maria T
authors.initials: MT
authors.lastname: Scupoli
mesh_terms: D015703:Antigens, CD / Q000378:metabolism; D001402:B-Lymphocytes / Q000187:drug effects* / Q000276:immunology* / Q000378:metabolism; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D006801:Humans; D016130:Immunophenotyping; D008213:Lymphocyte Activation / Q000187:drug effects* / Q000276:immunology*; D014066:Palatine Tonsil / Q000276:immunology / Q000378:metabolism; D053219:Receptors, Tumor Necrosis Factor, Member 25 / Q000378:metabolism; D053380:Tumor Necrosis Factor Ligand Superfamily Member 15 / Q000494:pharmacology*
chemical_list: D015703:Antigens, CD; D053219:Receptors, Tumor Necrosis Factor, Member 25; C506033:TNFRSF25 protein, human; C117026:TNFSF15 protein, human; D053380:Tumor Necrosis Factor Ligand Superfamily Member 15
references.citation: Mucosal Immunol. 2011 Mar;4(2):172-85
references.pmid: 20980995
references.citation: J Immunol. 2009 Oct 15;183(8):5350-7
references.pmid: 19786547
references.citation: Science. 1996 Nov 8;274(5289):990-2
references.pmid: 8875942
references.citation: Immunol Rev. 2011 Nov;244(1):188-96
references.pmid: 22017439
references.citation: J Exp Med. 1998 Oct 5;188(7):1267-75
references.pmid: 9763606
references.citation: Nature. 1996 Nov 28;384(6607):372-5
references.pmid: 8934525
references.citation: Gene. 1997 Dec 19;204(1-2):35-46
references.pmid: 9434163
references.citation: J Immunol. 2007 Sep 15;179(6):3742-51
references.pmid: 17785811
references.citation: Proc Natl Acad Sci U S A. 1997 Apr 29;94(9):4615-9
references.pmid: 9114039
references.citation: Immunity. 1997 Jan;6(1):79-88
references.pmid: 9052839
references.citation: Eur J Immunol. 2012 Mar;42(3):580-8
references.pmid: 22259035
references.citation: Immunity. 2002 Mar;16(3):479-92
references.pmid: 11911831
references.citation: J Immunol. 2004 Jun 1;172(11):7002-7
references.pmid: 15153521
references.citation: Biochem Biophys Res Commun. 2007 Dec 7;364(1):1-6
references.pmid: 17935696
references.citation: Curr Biol. 1996 Dec 1;6(12):1669-76
references.pmid: 8994832
references.citation: J Clin Invest. 2010 Oct;120(10):3629-40
references.pmid: 20890040
references.citation: Immunity. 2008 Jul 18;29(1):79-89
references.pmid: 18571443
references.citation: J Immunol. 2007 Jun 1;178(11):7325-33
references.pmid: 17513783
references.citation: FASEB J. 2011 Jan;25(1):409-19
references.pmid: 20826539
references.citation: J Clin Immunol. 2010 Jul;30(4):531-8
references.pmid: 20349123
references.citation: FASEB J. 2012 Aug;26(8):3575-86
references.pmid: 22593543
references.citation: J Exp Med. 2008 May 12;205(5):1037-48
references.pmid: 18411341
references.citation: J Exp Med. 2008 May 12;205(5):1049-62
references.pmid: 18411337
references.citation: J Exp Med. 2008 Oct 27;205(11):2457-64
references.pmid: 18824582
references.citation: Mucosal Immunol. 2011 Mar;4(2):186-96
references.pmid: 20962771
references.citation: J Immunol. 2003 Nov 1;171(9):4868-74
references.pmid: 14568967
references.citation: J Immunol Methods. 2005 Mar;298(1-2):1-8
references.pmid: 15847792
references.citation: J Immunol. 2007 Apr 1;178(7):4033-8
references.pmid: 17371957
references.citation: FASEB J. 2009 Jun;23(6):1625-37
references.pmid: 19141537
references.citation: Cancer Res. 2006 Sep 15;66(18):9117-24
references.pmid: 16982754
references.citation: Immunity. 2007 Mar;26(3):371-81
references.pmid: 17363300
references.citation: Proc Natl Acad Sci U S A. 2006 May 30;103(22):8441-6
references.pmid: 16698931
references.citation: Inflamm Bowel Dis. 2010 Apr;16(4):568-75
references.pmid: 19834969
references.citation: Nat Rev Rheumatol. 2010 Feb;6(2):67-8
references.pmid: 20125169
references.citation: J Biol Chem. 2006 May 19;281(20):13964-71
references.pmid: 16547002